CeriBell (NASDAQ:CBLL) CRO Joseph Manni Sells 1,378 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,378 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $24,804.00. Following the completion of the sale, the executive directly owned 56,291 shares in the company, valued at $1,013,238. This represents a 2.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Up 0.2%

NASDAQ:CBLL opened at $18.80 on Wednesday. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33. The firm’s 50-day moving average price is $19.09 and its 200-day moving average price is $19.24. The company has a market capitalization of $713.27 million, a PE ratio of -11.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $26.09 million. On average, equities analysts predict that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently made changes to their positions in the business. Strs Ohio bought a new position in shares of CeriBell in the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd raised its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after acquiring an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell during the 3rd quarter worth approximately $33,000. CWM LLC raised its stake in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CBLL shares. Canaccord Genuity Group lowered their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.